

Effects of short- and long-term feeding of L-carnitine and congeners on the production of eicosanoids from rat peritoneal leucocytes

BY INGRID M. GARRELDS, GRAHAM R. ELLIOTT*, FREEK J. ZIJLSTRA
AND IVÁN L. BONTA

*Department of Pharmacology, Faculty of Medicine, Erasmus University Rotterdam, PO Box 1738,
Rotterdam, The Netherlands*

(Received 29 November 1993 – Revised 25 February 1994 – Accepted 9 March 1994)

The effect of short- and long-term feeding with L-carnitine, L-acetyl carnitine and L-propionyl carnitine on the production of eicosanoids from *in vitro* stimulated carrageenan-induced rat peritoneal macrophages was investigated. Both young (4 weeks) and old (18 months) rats were used. A lower number of cells was isolated from the peritonea of treated than control young rats after 4 d feeding, but after 60 d no differences were observed. A similar reduction in cell number was found when old animals were given L-acetyl carnitine or L-propionyl carnitine (acutely) or L-acetyl carnitine or L-carnitine (chronically). Plasma carnitine levels were higher in young rats given carnitine both chronically and acutely. Carnitine derivatives were without effect. In contrast, levels of total carnitine in the plasma of old rats given L-carnitine and L-acetyl carnitine for 4 d and 60 d were higher than in controls. There was no correlation between total plasma carnitine level and effects on prostaglandin, thromboxane and leukotriene B₄ (LTB₄) production. In young rats the most important changes were observed in relation to the production of prostacyclin (PGI₂), measured as 6 keto-prostaglandin F_{1α}. Prostacyclin production was higher in the groups given carnitine or its derivatives. The net result of the changes in PGI₂ was that the 6 keto-prostaglandin F_{1α}:thromboxane B₂ and the 6 keto-prostaglandin F_{1α}:LTB₄ ratios tended to be higher in cells from young animals following short-term feeding with L-carnitine. When young rats were given carnitine compounds for 60 d PGI₂ production was lower in cells from L-acetyl carnitine- and L-propionyl carnitine-fed animals. The net result of the changes in PGI₂ was that the 6 keto-prostaglandin F_{1α}:thromboxane B₂ and the 6 keto-prostaglandin F_{1α}:LTB₄ ratios were lower in cells from animals fed with carnitine compounds. In old rats the PGI₂ production was lower after short-term feeding with carnitine compounds and was higher after long-term feeding. LTB₄ production was lower after L-carnitine and L-acetyl carnitine treatment for 4 d and also lower after 60 d treatment with L-acetyl carnitine. The net results of the changes in PGI₂ were that the 6 keto-prostaglandin F_{1α}:thromboxane B₂ and the 6 keto-prostaglandin F_{1α}:LTB₄ ratios were lower after short-term feeding of all three compounds and higher after the long-term treatment with L-acetyl carnitine and L-propionyl carnitine in old rats. By long-term treatment with low-dose aspirin of patients with heart failure and claudication, the 6 keto-prostaglandin F_{1α}:thromboxane B₂ ratio is positively increased, which is a beneficial cardioprotective effect. The mechanism of action of carnitine in heart failure and claudication could also be achieved by an increase of this ratio. Our results suggest that elderly patients could be treated chronically by carnitine to obtain this beneficial effect.

L-Carnitine: Peritoneal macrophages: Eicosanoids

Before long-chain fatty acids are oxidized in mitochondria they are activated by acyl coenzyme A (acyl CoA) synthetase (EC 6.2.1.3) and carried across the mitochondrial

* Present address: Department of Pharmacology, Medical Biological Laboratory, TNO, PO Box 45, 2280 AA, Rijswijk, The Netherlands.

inner membrane by L-carnitine (β -hydroxy-(γ -N-trimethylamino)-butyrate). Carnitine deficiency, defined as a decrease in intracellular carnitine, leads to the accumulation of acyl CoA esters within the cell and an inhibition of acyl transport through the mitochondrial inner membrane. Inhibition of the mitochondrial β -oxidation results in fatty acid infiltration and, eventually, heart or liver failure (Barth *et al.* 1983; Scholte *et al.* 1989, 1990; Wanner *et al.* 1989). Carnitine deficiency can be due to a genetic deficiency, or may occur as a side-effect of dialysis treatment. For example, serum carnitine and leucine levels were significantly decreased in patients on continuous ambulatory peritoneal dialysis (CAPD) for more than 4 months. This observation suggests that malabsorption plays a role in the reduction of serum carnitine levels in patients receiving CAPD (Murakami *et al.* 1990). The clinical conditions of infants and children with a variety of diagnoses associated with low circulating carnitine concentrations improved after carnitine supplementation, and carnitine has been reported to have several beneficial effects on ischaemic heart diseases and arrhythmias in man, where it augments the ischaemic heart tolerance to stress (Schinetti & Mazzini, 1986).

Carnitine administration may also have beneficial effects in patients with disorders of NH_3 metabolism (Ohtsuka & Griffith, 1991; Rebouche, 1992). Interestingly, adults suffering from chronic diseases associated with ageing, such as heart disease or cardiomyopathy due to carnitine loss, are improved by treatment with L-carnitine, L-acetyl carnitine or L-propionyl carnitine (Winter *et al.* 1987; Scholte *et al.* 1989, 1990; Wanner *et al.* 1989; Rebouche, 1992).

Besides its stimulation of fatty acid oxidation, L-carnitine has also been shown to enhance the formation of arachidonic acid from linoleic acid by isolated hepatocytes. It was suggested that this was due to the removal of the inhibitory effect of long-chain acyl CoA on acetyl CoA carboxylase (*EC* 6.4.1.2), a regulating enzyme in fatty acid synthesis, by long-chain acyl carnitine (McGarry *et al.* 1975; Christophersen & Norseth, 1981; Rebouche, 1986; Stryer, 1988; Conte *et al.* 1992). This increased arachidonic acid synthesis could be important, as eicosanoids, metabolites of arachidonic acid, are important local modulators of inflammation. For example, the cyclooxygenase product prostaglandin E_2 (PGE_2) is recognized as an important inhibitor of both cell migration and mediator formation, whereas leukotriene B_4 (LTB_4), a lipoxygenase (*EC* 1.13.11.12) product, is a potent chemotactic agent which promotes the formation of mediators at inflammatory sites (Lehmann *et al.* 1988; Renz *et al.* 1988; Schepers *et al.* 1988; Yamaoka *et al.* 1988). Furthermore, the ratio between the vasoconstrictive prostanoid thromboxane A_2 (TxA_2), synthesized by platelets, and the vasodilative prostacyclin (prostaglandin I_2 ; PGI_2), synthesized by endothelial cells, is of importance in controlling platelet aggregation and adherence to blood vessels (Campbell, 1990). CoA also plays a role in the formation and breakdown of products from both the cyclooxygenase and lipoxygenase pathways of arachidonic acid metabolism (Conte *et al.* 1992). Recently the oxidation of PGE_2 in rat liver peroxisomes and mitochondria was shown to require the activation to PGE_2 CoA by microsomal PGE_2 CoA synthetase (Schepers *et al.* 1988). Furthermore, LTB_4 is degraded through ω - and β -oxidation in neutrophils and liver cells. The formation of LTB_4 CoA esters which occurs in rat-liver microsomes may be essential for LTB_4 β -oxidation (Yamaoka *et al.* 1988). While LTB_4 is a potent chemotactic agent and promotes the formation of mediators at inflammatory sites, its degradation products are less potent than the parent compound. Hence the formation of LTB_4 CoA esters and their subsequent β -oxidation might be of importance in limiting LTB_4 activity at the sites of inflammation. Thus, carnitine could stimulate both the synthesis and breakdown of eicosanoids by the same mechanism, i.e. reducing the concentration of long-chain acyl CoA within the cell.

Recently we showed that feeding young rats (3–4 months) with L-carnitine or various

derivatives resulted in a preferential higher production of PGI₂ by peritoneal macrophages (Elliott *et al.* 1990). Our results could provide the basis for a possible explanation for the beneficial effects of carnitine and its derivatives in cardiovascular diseases. Such investigations into the mechanisms of L-carnitine and its derivatives may lead to the identification of new roles for these compounds.

In the present study we extended our investigations by examining the effect of L-carnitine, L-acetyl carnitine (formed during β -oxidation of even-chain fatty acids) and L-propionyl carnitine (formed during β -oxidation of uneven-chain fatty acids) on eicosanoid production by carrageenan-induced peritoneal cells of young and old rats after 4 or 60 d exposure. Earlier results obtained using young rats given carnitine compounds for 4 d are shown for ease of comparison (Elliott *et al.* 1990).

MATERIALS AND METHODS

Materials

L-Carnitine, L-acetyl carnitine, and L-propionyl carnitine were gifts from Sigma-Tau Pharmaceutical Co. (Rome, Italy). Carrageenan was purchased from Marine Colloids Inc (Springfield, NJ, USA). Lymphoprep was from Nyegaard Diagnostica (Oslo, Norway) and Dulbecco's modified Eagle's medium was obtained from Life Technologies (Breda, The Netherlands). A23187 was from Sigma (Axel, The Netherlands). ³H-labelled eicosanoids were from Amersham ('s-Hertogenbosch, The Netherlands) and antibodies from Advanced Magnetics Inc. (Cambridge, MA, USA). Other chemicals were purchased from Merck (Amsterdam, The Netherlands) and Sigma.

Animals

Male Wistar rats were used in all experiments. The animals were housed in groups of three in polyethylene cages with food and water *ad lib*. Artificial light was supplied in a 12 h light-dark cycle.

Treatment

Two series of experiments were carried out.

Short-term treatment. Young rats (3–4 months, nine rats per group) and old rats (16–18 months, five rats per group) were given by intubation on days 1–4, 300 mg L-carnitine or carnitine equivalents (L-acetyl carnitine and L-propionyl carnitine)/kg dissolved in 1 ml distilled water. Control animals were given distilled water. All animals were injected intraperitoneally with 2 ml of a carrageenan solution (1 mg/ml) on day 1 (Elliott *et al.* 1990).

Long-term treatment. Young rats (3–4 months, nine rats per group) and old rats (16–18 months, five rats per group) were given in their drinking water on days 1–60, 50 mg L-carnitine or carnitine equivalents (L-acetyl carnitine and L-propionyl carnitine)/kg. Control animals were given water. All animals were injected intraperitoneally with 2 ml of a carrageenan solution (1 mg/ml) on day 56 (4 d before the end of the experiment).

Isolation and incubation of peritoneal cells

On day 4 or 60, 1 h after the last administration of L-carnitine or its derivatives, cells were isolated from pooled Gey's balanced-salt solution washes of the peritonea of the rats by density-gradient centrifugation over Lymphoprep and suspended in Dulbecco's modified Eagle's medium (2×10^6 nucleated cells/ml). The harvested peritoneal cell population consisted of > 85% macrophages and > 10% polymorphonuclear leucocytes. A 1 ml portion of cell suspension was incubated at 37° for either 2 h without ionophore (basal

Table 1. Effect of short- and long-term feeding of L-carnitine or its congeners on the absolute cell number ($\times 10^6$) isolated from peritonea of young and old rats†

(Values are means and standard deviations for nine (young) and five (old) rats)

	Treatment	Control		L-Carnitine		L-Acetyl carnitine		L-Propionyl carnitine	
		Mean	SD	Mean	SD	Mean	SD	Mean	SD
Young rats	Short-term	13.33	3.73	6.34*	1.95	4.91*	0.38	6.48*	1.29
	Long-term	13.92	3.22	12.94	2.32	14.52	5.31	13.01	3.11
Old rats	Short-term	13.80	1.55	12.44	1.86	6.28*	0.51	7.89*	1.37
	Long-term	15.30	2.59	8.41*	2.07	8.39*	0.38	14.29	2.40

Mean values were significantly different from control values: * $P < 0.05$ (Students *t* test).

† For details of procedures, see pp. 787–788.

production) or 30 min with 10^{-6} M-A23187 (ionophore-stimulated production). The cell suspensions were then centrifuged and the supernatant fractions analysed for production of LTB_4 , PGE_2 , TxB_2 , and 6 keto-prostaglandin $\text{F}_{1\alpha}$ (6 keto-PGF $_{1\alpha}$) by radioimmunoassays (Zijlstra & Vincent, 1984; Elliott *et al.* 1990). The net eicosanoid production was calculated by subtraction of the basal production from the ionophore-stimulated production. Blood samples were taken for measurement of total plasma carnitine levels (Pande & Caramancion, 1981; Rössle *et al.* 1985).

Statistical evaluation

In the experiments the values are given as means and standard deviations for either nine or five rats per group. Statistical significance was calculated using the Student's *t* test.

RESULTS

Results obtained using young rats fed with carnitine compounds for 4 d have been previously published (Elliott *et al.* 1990) and are given here solely for the purposes of comparison.

Cell number

Young rats, short-term. All three compounds significantly reduced the number of nucleated cells isolated from peritonea 4 d after an intraperitoneal injection of carrageenan.

Young rats, long-term. No differences were found between the groups with respect to the number of nucleated peritoneal cells isolated after 60 d.

Old rats, short-term. L-Acetyl carnitine and L-propionyl carnitine significantly reduced the number of nucleated cells isolated from the peritonea after 4 d treatment.

Old rats, long-term. L-Carnitine and L-acetyl carnitine significantly reduced the number of nucleated cells isolated from the peritonea 60 d after treatment (Table 1).

Plasma levels of carnitine

Of the three compounds used, only in the L-carnitine group was the total L-carnitine concentration in plasma higher in all experiments in comparison with the controls (Table 2). In the L-acetyl carnitine group the total L-carnitine concentration in the plasma of old rats (chronic and acute) was higher than in controls.

Table 2. Effect of short- and long-term feeding of L-carnitine or its congeners on the plasma levels ($\mu\text{mol/l}$) of carnitine in young and old rats†

(Values are means and standard deviations for nine (young) and five (old) rats)

Treatment		Control		L-Carnitine		L-Acetyl carnitine		L-Propionyl carnitine	
		Mean	SD	Mean	SD	Mean	SD	Mean	SD
Young rats	Short-term	66.3	4.5	102.4*	18.7	75.3	11.2	76.1	19.9
	Long-term	76.7	9.1	125.3*	14.2	82.6	15.3	86.0	14.6
Old rats	Short-term	81.6	17.5	138.8*	20.0	114.2*	11.4	109.3	23.7
	Long-term	69.2	15.2	95.9*	9.9	98.4*	18.0	88.5	24.8

Mean values were significantly different from control values: * $P < 0.05$ (Students t test).

† For details of procedures, see pp. 787–788.




Fig. 1. Effect of short- (4 d; panels (a) and (c)) and long-term (60 d; panels (b) and (d)) feeding of L-carnitine, L-acetyl carnitine and L-propionyl carnitine on the production of prostaglandin E_2 (■), thromboxane B_2 (▨), and 6 keto-prostaglandin $F_{1\alpha}$ (▩) from carrageenan-induced peritoneal cells of young and old rats. Values are means with standard deviations indicated by vertical bars. Mean values were significantly different from control values: * $P < 0.05$ (Student's t test). For details of procedures, see pp. 787–788.

Production of eicosanoids from carrageenan-induced peritoneal cells

Young rats. In the short-term experiments the production of 6 keto-PGF $_{1\alpha}$ and TxB $_2$ tended to increase with L-acetyl carnitine and L-propionyl carnitine (Fig. 1). Production of 6 keto-PGF $_{1\alpha}$ was significantly higher and that of TxB $_2$ tended to be higher after feeding with L-carnitine. LTB $_4$ production was significantly higher in all three treatment groups (Table 3). However, no effects on PGE $_2$ formation were detected. The 6 keto-PGF $_{1\alpha}$:TxB $_2$

Table 3. Effect of short- and long-term feeding of L-carnitine or its congeners on the net production of leukotriene B_4 ($ng/2 \times 10^6$ macrophages) from peritoneal cells in young and old rats†

(Values are means and standard deviations for nine (young) and five (old) rats)

Treatment	Control		L-Carnitine		L-Acetyl carnitine		L-Propionyl carnitine	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Young rats								
Short-term	0.77	0.36	1.54*	0.87	1.72*	1.19	1.19*	0.72
Long-term	0.37	0.19	0.63	0.70	0.31	0.40	0.25*	0.23
Old rats								
Short-term	1.42	0.21	0.93*	0.30	1.17*	0.35	1.03	0.60
Long-term	0.33	0.13	0.38	0.17	0.05*	0.03	0.26	0.14

Mean values were significantly different from control values: * $P < 0.05$ (Students *t* test).

† For details of procedures, see pp. 787–788.

Table 4. Effect of short- and long-term feeding of L-carnitine or its congeners on the 6 keto-prostaglandin $F_{1\alpha}$:thromboxane B_2 ratio of peritoneal cells from young and old rats†

(Values are means and standard deviations for nine (young) and five (old) rats)

Treatment	Control		L-Carnitine		L-Acetyl carnitine		L-Propionyl carnitine	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Young rats								
Short-term	1.72	1.55	3.80	4.05	1.26	1.38	0.87	0.70
Long-term	0.71	0.23	0.97*	0.11	0.29*	0.06	0.28*	0.08
Old rats								
Short-term	1.65	0.43	0.90*	0.16	0.22*	0.08	0.46*	0.17
Long-term	0.15	0.06	0.48*	0.25	0.76*	0.27	0.52*	0.19

Mean values were significantly different from control values: * $P < 0.05$ (Students *t* test).

† For details of procedures, see pp. 787–788.

and the 6 keto-PGF $_{1\alpha}$:LTB $_4$ ratios, calculated from the net values, tended to be higher with L-carnitine treatment (Tables 4 and 5). This was due to the fact that the stimulation of 6 keto-PGF $_{1\alpha}$ production was greater than that of the other eicosanoids measured (Elliott *et al.* 1990).

In the long-term experiments the 6 keto-PGF $_{1\alpha}$ production was significantly lower in the L-acetyl carnitine and L-propionyl carnitine groups, while it was not in the L-carnitine group. No changes in PGE $_2$ production were detected (Fig. 1). LTB $_4$ production was significantly lower after feeding L-propionyl carnitine (Table 3). This resulted in significantly lower 6 keto-PGF $_{1\alpha}$:TxB $_2$ and 6 keto-PGF $_{1\alpha}$:LTB $_4$ ratios after treatment with L-acetyl carnitine and L-propionyl carnitine, but a significantly higher 6 keto-PGF $_{1\alpha}$:TxB $_2$ ratio in the L-carnitine group compared with controls (Tables 4 and 5).

Old rats. In the short-term experiments the production of 6 keto-PGF $_{1\alpha}$ was significantly lower in all carnitine groups and the TxB $_2$ production was significantly lower in the L-propionyl carnitine group. No changes in PGE $_2$ production were detected (Fig. 1). LTB $_4$ production was significantly lower after L-carnitine and L-acetyl carnitine treatments. The 6 keto-PGF $_{1\alpha}$:TxB $_2$ and 6 keto-PGF $_{1\alpha}$:LTB $_4$ ratios were significantly lower in all three treatment groups than in the control group.

Table 5. Effect of short- and long-term feeding of L-carnitine or its congeners on the 6 keto-prostaglandin $F_{1\alpha}$:leukotriene B_4 ratio of peritoneal cells from young and old rats†

(Values are means and standard deviations for nine (young) and five (old) rats)

Treatment	Control		L-Carnitine		L-Acetyl carnitine		L-Propionyl carnitine		
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	
Young rats	Short-term	4.88	2.90	12.99	8.35	8.74	8.29	7.13	4.47
	Long-term	18.32	7.25	11.83	9.20	6.55*	6.15	5.48*	3.67
Old rats	Short-term	9.16	1.86	5.53*	1.56	1.10*	0.40	0.61*	0.32
	Long-term	5.21	1.99	18.32	9.53	87.86*	38.22	20.56*	9.69

Mean values were significantly different from control values: * $P < 0.05$ (Students t test).

† For details of procedures, see pp. 787–788.

In the long-term experiments no significant effects on PGE_2 and TxB_2 production were detected. Only in the L-acetyl carnitine and the L-propionyl carnitine groups was a significantly lower production of 6 keto-PGF $_{1\alpha}$ found (Fig. 1). LTB_4 production was significantly lower in the L-acetyl carnitine group after chronic exposure (Table 3). The 6 keto-PGF $_{1\alpha}$: TxB_2 ratio was significantly higher in all three treatment groups and the 6 keto-PGF $_{1\alpha}$: LTB_4 ratio was significantly higher in the chronic experiments after treatment with L-acetyl carnitine and L-propionyl carnitine (Tables 4 and 5).

DISCUSSION

Only exposure to L-carnitine resulted in an elevation of total plasma L-carnitine in young rats (acute and chronic exposure). Both L-carnitine and acetyl carnitine treatment elevated total plasma L-carnitine in old rats. However, in view of the lack of a correlation between plasma L-carnitine and other variables measured, the significance of these increases is not clear. One effect of feeding L-carnitine or its congeners to young rats for 4 d was the much lower number of carrageenan-elicited macrophages isolated from the peritonea of the treated animals. In contrast there was no effect when young rats were treated chronically. The effect of carnitine compounds on the number of elicited macrophages isolated from old rats was variable. Only in the L-acetyl carnitine group was a lower number of elicited macrophages found after both chronic and acute exposure. These results indicate that some L-carnitine compounds can modify the macrophage response to chemotactic signals generated when carrageenan is injected intraperitoneally. The exact effect depends on the age of the animal and time of exposure. A reduction of 50% in the number of macrophages at an inflammatory site could well be beneficial, for example in chronic immunoinflammatory diseases.

We previously demonstrated that PGI_2 production by rat and rabbit aortas increased with age (Adolfs & Elliott, 1982; Elliott & Adolfs, 1984; Vincent & Zijlstra, 1986). In the present study we also show that eicosanoid production by macrophages is increased with age. It now appears that an increase in the turnover of arachidonic acid could be a characteristic of ageing. From the short-term feeding experiments with older rats we conclude, in general, that L-carnitine and its derivatives inhibited PGI_2 production. In contrast, the production of PGI_2 after long-term feeding was stimulated. The net results of the changes in PGI_2 were that the 6 keto-prostaglandin $F_{1\alpha}$:thromboxane B_2 and the 6 keto-prostaglandin $F_{1\alpha}$: LTB_4 ratios were lower after short-term feeding of all three

compounds and higher in the long-term treatment with L-acetyl carnitine and L-propionyl carnitine in comparison with controls. The production of PGI₂ and TxB₂ from macrophages isolated from young test animals was higher than that from control rats after short-term feeding with L-carnitine and its derivatives. The results of these changes were that the 6 keto-PGF_{1α}:TxB₂ ratio and 6 keto-PGF_{1α}:TxB₂ ratio were higher after short-term L-carnitine treatment. After long-term treatment with L-acetyl carnitine and L-propionyl carnitine a lower production of PGI₂ was observed. The net results were that the 6 keto-prostaglandin F_{1α}:thromboxane B₂ and 6 keto-prostaglandin F_{1α}:LTB₄ ratios were lower after feeding with L-acetyl carnitine and L-propionyl carnitine.

In man the 6 keto-PGF_{1α}:TxB₂ ratio is positively increased by long-term low-dose aspirin treatment, despite the fact that aspirin inhibits prostaglandin formation. This is because although aspirin inhibits the synthesis of platelet thromboxane A₂, a vasoconstrictor and platelet activator, and of vascular endothelium prostacyclin synthesis, a vasodilator and platelet inhibitor (Haslam & McClenaghan, 1981; Weksler *et al.* 1983; Kallmann *et al.* 1987), the effect of aspirin on endothelium cyclooxygenase is much less than the effect on the platelets. The mechanism of action of carnitine in heart failure and claudication could be achieved by an increase in the 6 keto-PGF_{1α}:TxB₂ ratio. Our results suggest that elderly patients could be treated chronically with carnitine to obtain this beneficial effect. Further clinical trials, in which both plasma eicosanoid levels and prostacyclin production are monitored, should be performed to test this hypothesis.

These studies were supported by Sigma-Tau Pharmaceutical Co., Rome, Italy.

REFERENCES

- Adolfs, M. J. & Elliott, G. R. (1982). The stimulation by ethanol of rat aorta ring prostacyclin-like synthesis is related to the age of the animal. *Agents and Actions* **11**, Suppl., 217–224.
- Barth, P. G., Scholte, H. R., Berden, J. A., van der Klei-van Moorsel, J. M., Luyt-Houwen, I. E. M., van 't Veer-Korthof, E. Th., van der Harten, J. J. & Sobotka-Plojhar, M. A. (1983). An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leukocytes. *Journal of the Neurological Sciences* **62**, 327–355.
- Campbell, W. B. (1990). Lipid-derived autocooids: eicosanoids and platelet activating factor. In *The Pharmacological Basis of Therapeutics*, 8th ed., pp. 600–617 [A. G. Gilman, L. S. Goodman, T. W. Rall, A. S. Nies and P. Taylor, editors]. New York: Macmillan.
- Christoffersen, B. O. & Norseth, J. (1981). Arachidonic acid synthesis studied in isolated liver cells. Effects of (–)-carnitine and of (+)-decanoylcarnitine. *FEBS Letters* **133**, 201–204.
- Conte, A., Fraticelli, G. & Ronca, G. (1992). Recent findings on the regulatory functions of CoA and the normalizing activity on plasma lipids of exogenous CoA. *Drugs Under Experimental and Clinical Research* **18**, 179–188.
- Elliott, G. R. & Adolfs, M. J. (1984). Continuous monitoring of prostacyclin production by the isolated, intact, rat aorta using a bioassay technique. *Journal of Pharmacological Methods* **11**, 253–261.
- Elliott, G. R., Lauwen, A. P. M. & Bonta, I. L. (1990). The effect of acute feeding of carnitine, acetyl carnitine and propionyl carnitine on basal and A23187-stimulated eicosanoid release from rat carrageenan-elicited peritoneal macrophages. *British Journal of Nutrition* **64**, 497–503.
- Haslam, R. J. & McClenaghan, M. D. (1981). Measurement of circulating prostacyclin. *Nature* **292**, 364–366.
- Kallmann, R., Nieuwenhuis, H. K., de Groot, P. G., van Gijn, J. & Sixma, J. J. (1987). Effects of low doses of aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane production and 6-keto-PGF_{1α} excretion in healthy subjects. *Thrombosis Research* **45**, 355–361.
- Lehmann, V., Benninghoff, B. & Droge, W. (1988). Tumor necrosis factor-induced activation of peritoneal macrophages is regulated by prostaglandin E₂ and cAMP. *Journal of Immunology* **18**, 957–959.
- McGarry, J. D., Robles-Valdes, C. & Foster, D. W. (1975). Role of carnitine in hepatic ketogenesis. *Proceedings of the National Academy of Sciences of the United States of America* **72**, 4385–4388.
- Murakami, R., Momota, T., Yoshiya, K., Yoshikawa, N., Nakamura, H., Honda, M. & Ito, H. (1990). Serum carnitine and nutritional status in children treated with continuous ambulatory peritoneal dialysis. *Journal of Pediatric Gastroenterology and Nutrition* **11**, 371–374.
- Ohtsuka, Y. & Griffith, O. W. (1991). L-Carnitine protection in ammonia intoxication. Effect of aminocarnitine on carnitine-dependent metabolism and acute ammonia toxicity. *Biochemical Pharmacology* **41**, 1957–1961.

- Pande, S. V. & Caramancion, M. N. (1981). A simple radioisotopic assay of acetylcarnitine and acetyl-CoA at picomolar levels. *Analytical Biochemistry* **112**, 30–38.
- Rebouche, C. J. (1986). Carnitine metabolism and function in humans. *Annual Review of Nutrition* **6**, 41–66.
- Rebouche, C. J. (1992). Carnitine function and requirements during the life cycle. *FASEB Journal* **6**, 3379–3386.
- Renz, H., Gond, J. H., Schmidt, A., Nain, M. & Gemsa, D. (1988). Release of tumor necrosis factor- α from macrophages. Enhancement and suppression are dose-dependent regulated by prostaglandin E_2 and cyclic nucleotides. *Journal of Immunology* **141**, 2388–2393.
- Rössle, C., Kohse, K. P., Franz, H. E. & Fürst, P. (1985). An improved method for the determination of free and esterified carnitine. *Clinica Chimica Acta* **149**, 263–268.
- Schepers, L., Casteels, M., Vamecq, J., Parmentier, G., van Veldhoven, P. P. & Mannaerts, G. P. (1988). β -Oxidation of the carboxyl side chain of prostaglandin E_2 in rat liver peroxisomes and mitochondria. *Journal of Biological Chemistry* **263**, 2724–2731.
- Schinetti, M. L. & Mazzini, A. (1986). Effect of L-carnitine on human neutrophil activity. *International Journal of Tissue Reactions* **8**, 199–203.
- Scholte, H. R., Rodrigues Pereira, R., Busch, H. F., Jennekens, F. G., Luyt-Houwen, I. E. & Vaandrager-Verduin, M. H. (1989). Carnitine deficiency, mitochondrial dysfunction and the heart. Identical defect of oxidative phosphorylation in muscle mitochondria in cardiomyopathy due to carnitine loss and in Duchenne muscular dystrophy. *Wiener Klinische Wochenschrift* **6**, 12–17.
- Scholte, H. R., Rodrigues Pereira, R., de Jonge, P. C., Luyt-Houwen, I. E., Hedwig, M., Verduin, M. & Ross, J. D. (1990). Primary carnitine deficiency. *Journal of Clinical Chemistry and Clinical Biochemistry* **28**, 351–357.
- Stryer, L. (1988). *Biochemistry*, 3rd ed., pp. 332, 472–475 and 484. New York: W. H. Freeman and Company.
- Vincent, J. E. & Zijlstra, F. J. (1986). The effect of age on the prostaglandin formation in the rabbit aorta. *Artery* **13**, 199–202.
- Wanner, C., Riegel, W., Schaefer, R. M. & Horl, W. H. (1989). Carnitine and carnitine esters in acute renal failure. *Nephrology Dialysis Transplantation* **4**, 951–956.
- Weksler, B. B., Pett, S. B., Alonso, D., Richter, R. C., Stelzer, P., Subramanian, V., Tack-Goldman, K. & Gay, W. A. (1983). Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. *New England Journal of Medicine* **308**, 800–805.
- Winter, S. C., Szabo-Aczel, S., Curry, C. J. R., Hutchinson, H. T., Hogue, R. & Shug, A. (1987). Plasma carnitine deficiency. Clinical observations in 51 pediatric patients. *American Journal of Diseases of Children* **141**, 660–665.
- Yamaoka, A., Sumimoto, H., Isobe, R. & Minakami, S. (1988). Formation of leukotriene B_4 -coenzyme A ester by rat liver microsomes. *Biochemical and Biophysical Research Communications* **154**, 1248–1252.
- Zijlstra, F. J. & Vincent, J. E. (1984). Determination of leukotrienes and prostaglandins in [^{14}C]-arachidonic acid labelled human lung tissue by high-performance liquid chromatography and radioimmunoassay. *Journal of Chromatography* **311**, 39–50.